Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Alan Stanford

Dermatology Daphne, AL Medical Doctor

NPI 1871557348 CMS profile 266013

8573 County Road 64, Daphne, AL 36526

Open in the dashboard

General payments

$7,040

394 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$12,110 paid to institutions, not to them · program years 2019–2020

Through program year 2023, Alan Stanford of Daphne, AL is reported in the CMS Open Payments database as having received $7,040 across 394 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $12,110 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 72nd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $911 51
2022 General $2,300 131
2021 General $1,446 91
2020 General $1,183 70
2019 General $1,200 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alan Stanford
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Alan Stanford were reported at $0. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Alan Stanford Dermatology median Middle half National median
2019 $1,200 $454 $129–$1,240 $163
2020 $1,183 $235 $81–$756 $114
2021 $1,446 $377 $108–$1,108 $132
2022 $2,300 $514 $143–$1,391 $149
2023 $911 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $0 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AbbVie, Inc. $2,400 129 payments
  2. Novartis Pharmaceuticals Corporation $1,109 71 payments
  3. UCB, Inc. $690 33 payments
  4. Janssen Biotech, Inc. $322 17 payments
  5. Sun Pharmaceutical Industries Inc. $315 25 payments
  6. Regeneron Healthcare Solutions, Inc. $302 14 payments
  7. Dermavant Sciences, Inc. $245 11 payments
  8. Lilly USA, LLC $195 10 payments
  9. Amgen Inc. $183 10 payments
  10. LEO Pharma Inc. $182 13 payments
  11. Other $1,097 61 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $6,861 392 payments
  2. Education $179 2 payments
Products named General payments · program years 2019–2023
  1. SKYRIZI $1,250 69 payments
  2. HUMIRA $991 50 payments
  3. Cimzia $690 33 payments
  4. COSENTYX $563 44 payments
  5. RINVOQ $351 20 payments
  6. DUPIXENT $263 12 payments
  7. ILUMYA $262 21 payments
  8. VTAMA $245 11 payments
  9. TALTZ $195 10 payments
  10. TREMFYA $188 8 payments
  11. Other $2,953 169 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

24

Median for Dermatology: 534

Drug cost

$2,629

Median for Dermatology: $67,151

Branded share of claims

50%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Shingrix Varicella-Zoster Ge/As01b/Pf Brand 12 $2,365
Triamcinolone Acetonide Generic 12 $264

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$2,707

Medicare's payments for the services billed

Medicare patients

13

Average age 76

Services billed

26

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 0%
Osteoporosis 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

394 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record